{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T03:13:26Z","timestamp":1792638806006,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1007\/s00280-014-2429-5","type":"journal-article","created":{"date-parts":[[2014,3,31]],"date-time":"2014-03-31T17:59:04Z","timestamp":1396288744000},"page":"975-982","source":"Crossref","is-referenced-by-count":26,"title":["A phase II trial of prolonged, continuous infusion of low-dose gemcitabine plus cisplatin in patients with advanced malignant pleural mesothelioma"],"prefix":"10.1007","volume":"73","author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"L\u00f3pez-Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00edctor-Osvaldo","family":"Mendoza-Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludwing","family":"Bacon-Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Mu\u00f1oz-Monta\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleazar-Omar","family":"Macedo-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sa\u00e9","family":"Mu\u00f1iz-Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Blake-Cerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9-Francisco","family":"Corona-Cruz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,4,1]]},"reference":[{"issue":"12","key":"2429_CR1","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/1097-0142(19801215)46:12<2736::AID-CNCR2820461233>3.0.CO;2-L","volume":"46","author":"IJ Selikoff","year":"1980","unstructured":"Selikoff IJ, Hammond EC, Seidman H (1980) Latency of asbestos disease among insulation workers in the United States and Canada. Cancer 46(12):2736\u20132740","journal-title":"Cancer"},{"issue":"12","key":"2429_CR2","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1200\/JCO.2008.19.8523","volume":"27","author":"AS Tsao","year":"2009","unstructured":"Tsao AS, Wistuba I, Roth JA et al (2009) Malig Pleur Mesothelioma J Clin Oncol 27(12):2081\u20132090. doi: 10.1200\/JCO.2008.19.8523","journal-title":"Malig Pleur Mesothelioma J Clin Oncol"},{"issue":"10","key":"2429_CR3","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2471\/BLT.11.086678","volume":"89","author":"V Delgermaa","year":"2011","unstructured":"Delgermaa V, Takahashi K, Park EK et al (2011) Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ 89(10):716\u2013724. doi: 10.2471\/BLT.11.086678 724A\u2013724C","journal-title":"Bull World Health Organ"},{"issue":"3","key":"2429_CR4","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1002\/ajim.20780","volume":"53","author":"G Aguilar-Madrid","year":"2010","unstructured":"Aguilar-Madrid G, Robles-P\u00e9rez E, Ju\u00e1rez-P\u00e9rez CA et al (2010) Case-control study of pleural mesothelioma in workers with social security in Mexico. Am J Ind Med 53(3):241\u2013251","journal-title":"Am J Ind Med"},{"issue":"6","key":"2429_CR5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1590\/S0036-36342000000600007","volume":"42","author":"MP Garc\u00eda-L\u00f3pez","year":"2000","unstructured":"Garc\u00eda-L\u00f3pez MP, Barrera-Rodr\u00edguez R (2000) Malignant mesothelioma: clinical and radiological description of 45 cases with and without asbestos exposure. Salud Publica Mex 42(6):511\u2013519","journal-title":"Salud Publica Mex"},{"issue":"4","key":"2429_CR6","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1289\/ehp.1002845","volume":"119","author":"EK Park","year":"2011","unstructured":"Park EK, Takahashi K, Hoshuyama T et al (2011) Global magnitude of reported and unreported mesothelioma. Environ Health Perspect 119(4):514\u2013518. doi: 10.1289\/ehp.1002845","journal-title":"Environ Health Perspect"},{"key":"2429_CR7","unstructured":"NCCN Guidelines for Treatment of Malignat Pleural Mesothelioma (2013) IOP National Comprehensive Cancer Network Web. http:\/\/www.nccn.org\/professionals\/physician_gls\/f_guidelines.asp#site . Accessed 23 Dec 2013"},{"issue":"14","key":"2429_CR8","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","volume":"21","author":"NJ Vogelzang","year":"2003","unstructured":"Vogelzang NJ, Rusthoven JJ, Symanowski J et al (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21(14):2636\u20132644","journal-title":"J Clin Oncol"},{"issue":"28","key":"2429_CR9","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.20005.14.589","volume":"23","author":"JP Meerbeeck van","year":"2005","unstructured":"van Meerbeeck JP, Gaafaar R, Manegold C et al (2005) Randomized phase III Study of Cisplatin With or Without Ralitrexed in Patients with Malignant Pleural Mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada. J Clin Oncol 23(28):2636\u20132644","journal-title":"J Clin Oncol"},{"issue":"3","key":"2429_CR10","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.lungcan.2011.04.014","volume":"73","author":"RJ Kelly","year":"2011","unstructured":"Kelly RJ, Sharon E, Hassan R (2011) Chemotherapy and targeted therapies for unresectable malignant mesothelioma. Lung Cancer 73(3):256\u2013263. doi: 10.1016\/j.lungcan.2011.04.014","journal-title":"Lung Cancer"},{"issue":"5","key":"2429_CR11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1038\/sj.bjc.6600505","volume":"87","author":"AK Nowak","year":"2002","unstructured":"Nowak AK, Byrne MJ, Williamson R et al (2002) A multicenter phase II study of cisplatin and gemcitabine for malignant mesothelioma. Br J Cancer 87(5):491\u2013496","journal-title":"Br J Cancer"},{"issue":"6","key":"2429_CR12","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/bjc.2012.44","volume":"106","author":"\u00d3 Arrieta","year":"2012","unstructured":"Arrieta \u00d3, Medina LA, Estrada-Lobato E et al (2012) First-line chemotherapy with liposomal doxorubicin plus cisplatin for patients with advanced malignant pleural mesothelioma: phase II trial. Br J Cancer 106(6):1027\u20131032. doi: 10.1038\/bjc.2012.44","journal-title":"Br J Cancer"},{"issue":"8","key":"2429_CR13","first-page":"3441","volume":"29","author":"M Ralli","year":"2009","unstructured":"Ralli M, Tourkantonis I, Makrilia N et al (2009) Docetaxel plus gemcitabine as first-line treatment in malignant pleural mesothelioma: a single institution phase II study. Anticancer Res 29(8):3441\u20133444","journal-title":"Anticancer Res"},{"issue":"1","key":"2429_CR14","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/sj.bjc.6604421","volume":"99","author":"JB S\u00f8rensen","year":"2008","unstructured":"S\u00f8rensen JB, Frank H, Palshof T (2008) Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleuralmesothelioma. Br J Cancer 99(1):44\u201350. doi: 10.1038\/sj.bjc.6604421","journal-title":"Br J Cancer"},{"issue":"9","key":"2429_CR15","first-page":"3553","volume":"33","author":"CC Boons","year":"2013","unstructured":"Boons CC, VAN Tulder MW, Burgers JA et al (2013) The value of pemetrexed for the treatment of malignant pleural mesothelioma: a comprehensive review. Anticancer 33(9):3553\u20133561","journal-title":"Anticancer"},{"issue":"2","key":"2429_CR16","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.lungcan.2013.03.021","volume":"81","author":"F Grossi","year":"2013","unstructured":"Grossi F, Genova C, Gaitan ND et al (2013) Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy. Lung Cancer 81(2):236\u2013240. doi: 10.1016\/j.lungcan.2013.03.021","journal-title":"Lung Cancer"},{"issue":"2","key":"2429_CR17","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.lungcan.2011.07.011","volume":"75","author":"B Woods","year":"2012","unstructured":"Woods B, Paracha N, Scott DA et al (2012) Raltitrexed plus cisplatin is cost-effective compared with pemetrexed plus cisplatin in patients with malignant pleural mesothelioma. Lung Cancer 75(2):261\u2013267. doi: 10.1016\/j.lungcan.2011.07.011","journal-title":"Lung Cancer"},{"issue":"9","key":"2429_CR18","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1097\/JTO.0b013e3181ae280f","volume":"4","author":"M Zwitter","year":"2009","unstructured":"Zwitter M, Kovac V, Smrdel U et al (2009) Gemcitabine in brief versus prolonged low-dose infusion, both combined with cisplatin, for advanced non-small cell lung cancer: a randomized phase II clinical trial. J Thorac Oncol 4(9):1148\u20131155. doi: 10.1097\/JTO.0b013e3181ae280f","journal-title":"J Thorac Oncol"},{"issue":"1","key":"2429_CR19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1023\/A:1006478702342","volume":"19","author":"O Sezer","year":"2001","unstructured":"Sezer O, Eucker J, Jakob C et al (2001) Achievement of complete remission in refractory Hodgkin\u2019s disease with prolonged infusion of gemcitabine. Invest New Drugs 19(1):101\u2013104","journal-title":"Invest New Drugs"},{"issue":"4","key":"2429_CR20","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1023\/A:1005981317532","volume":"15","author":"R Brand","year":"2007","unstructured":"Brand R, Capadano M, Tempero M (2007) A phase I trial of weekly gemcitabine administered as a prolonged infusion in patients with pancreatic cancer and other solid tumors. Invest New Drugs 15(4):331\u2013341","journal-title":"Invest New Drugs"},{"issue":"6","key":"2429_CR21","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/00001813-199907000-00003","volume":"10","author":"K Akrivakis","year":"1999","unstructured":"Akrivakis K, Schmid P, Flath B et al (1999) Prolonged infusion of gemcitabine in stage IV breast cancer: a phase I study. Anticancer Drugs 10(6):525\u2013531","journal-title":"Anticancer Drugs"},{"issue":"Suppl 5","key":"2429_CR22","doi-asserted-by":"crossref","first-page":"v142","DOI":"10.1093\/annonc\/mdj970","volume":"17","author":"L Cattel","year":"2006","unstructured":"Cattel L, Airoldi M, Delprino L et al (2006) Pharmacokinetic evaluation of gemcitabine and 2\u2032,2\u2032-difluorodeoxycytidine-5\u2032-triphosphate after prolonged infusion in patients affected by different solid tumors. Ann Oncol 17(Suppl 5):v142\u2013v147","journal-title":"Ann Oncol"},{"issue":"9","key":"2429_CR23","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00001813-200110000-00001","volume":"12","author":"J Maurel","year":"2001","unstructured":"Maurel J, Zorrilla M, Puertolas T et al (2001) Phase I trial of weekly gemcitabine at 3-h infusion in refractory, heavily pretreated advanced solid tumors. Anticancer Drugs 12(9):713\u2013717","journal-title":"Anticancer Drugs"},{"issue":"3","key":"2429_CR24","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.1996.382","volume":"74","author":"H Anderson","year":"1996","unstructured":"Anderson H, Thatcher N, Walling J et al (1996) A phase I study of a 24 hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer. Br J Cancer 74(3):460\u2013462","journal-title":"Br J Cancer"},{"issue":"2","key":"2429_CR25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1005817024382","volume":"15","author":"CF Pollera","year":"1997","unstructured":"Pollera CF, Ceribelli A, Crecco M et al (1997) Prolonged infusion gemcitabine: a clinical phase I study at low-(300\u00a0mg\/m2) and high-dose (875\u00a0mg\/m2) levels. Invest New Drugs 15(2):115\u2013121","journal-title":"Invest New Drugs"},{"issue":"9","key":"2429_CR26","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1023\/A:1008487932384","volume":"9","author":"N Touroutoglou","year":"1998","unstructured":"Touroutoglou N, Gravel D, Raber MN et al (1998) Clinical results of a pharmacodynamically based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann Oncol 9(9):1003\u20131008","journal-title":"Ann Oncol"},{"issue":"3","key":"2429_CR27","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1200\/JCO.1991.9.3.491","volume":"9","author":"JL Abbruzzese","year":"1991","unstructured":"Abbruzzese JL, Grunewald R, Weeks EA et al (1991) A phase I clinical, plasma, and cellular pharmacology study of gemcitabine. J Clin Oncol 9(3):491\u2013498","journal-title":"J Clin Oncol"},{"issue":"4 Suppl 11","key":"2429_CR28","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ et al (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22(4 Suppl 11):3\u201310","journal-title":"Semin Oncol"},{"issue":"9","key":"2429_CR29","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1136\/thorax.55.9.731","volume":"55","author":"JG Edwards","year":"2000","unstructured":"Edwards JG, Abrams KR, Leverment JN et al (2000) Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax 55(9):731\u2013735","journal-title":"Thorax"},{"issue":"1","key":"2429_CR30","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1200\/JCO.2005.07.050","volume":"23","author":"DA Fennell","year":"2005","unstructured":"Fennell DA, Parmar A, Shamash J et al (2005) Statistical validation of the EORTC prognostic model for malignant pleural mesothelioma based on three consecutive phase II trials. J Clin Oncol 23(1):184\u2013189","journal-title":"J Clin Oncol"},{"issue":"1","key":"2429_CR31","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.lungcan.2012.02.005","volume":"77","author":"\u00d3 Arrieta","year":"2012","unstructured":"Arrieta \u00d3, N\u00fa\u00f1ez-Valencia C, Reynoso-Erazo L et al (2012) Health-related quality of life in patients with lung cancer: validation of the Mexican\u2013Spanish version and association with prognosis of the EORTC QLQ-LC13 questionnaire. Lung Cancer 77(1):205\u2013211. doi: 10.1016\/j.lungcan.2012.02.005","journal-title":"Lung Cancer"},{"issue":"6","key":"2429_CR32","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/S0003-4975(03)00010-9","volume":"75","author":"JH Schouwink","year":"2003","unstructured":"Schouwink JH, Kool LS, Rutgers EJ et al (2003) The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg 75(6):1715\u20131718","journal-title":"Ann Thorac Surg"},{"issue":"1","key":"2429_CR33","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.1999.17.1.25","volume":"17","author":"MJ Byrne","year":"1999","unstructured":"Byrne MJ, Davidson JA, Musk AW, Dewar J, van Hazel G, Buck M, de Klerk NH, Robinson BW et al (1999) Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 17(1):25\u201330","journal-title":"J Clin Oncol"},{"issue":"3","key":"2429_CR34","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/sj.bjc.6600118","volume":"86","author":"JM Haarst van","year":"2002","unstructured":"van Haarst JM, Baas P, Manegold Ch et al (2002) Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 86(3):342\u2013345","journal-title":"Br J Cancer"},{"issue":"2","key":"2429_CR35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.lungcan.2007.09.018","volume":"60","author":"SR Kalmadi","year":"2008","unstructured":"Kalmadi SR, Rankin C, Kraut MJ et al (2008) Gemcitabine and cisplatin in unresectable malignant mesothelioma of the pleura: a phase II study of the Southwest Oncology Group (SWOG 9810). Lung Cancer 60(2):259\u2013263","journal-title":"Lung Cancer"},{"issue":"3","key":"2429_CR36","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/01.coc.0000144852.75613.56","volume":"28","author":"B Castagneto","year":"2005","unstructured":"Castagneto B, Zai S, Dongiovanni D et al (2005) Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 28(3):223\u2013226","journal-title":"Am J Clin Oncol"},{"issue":"11","key":"2429_CR37","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1002\/cncr.11405","volume":"97","author":"AG Favaretto","year":"2003","unstructured":"Favaretto AG, Aversa SM, Paccagnella A et al (2003) Gemcitabine combined with carboplatin in patients with malignant pleural mesothelioma: a multicentric phase II study. Cancer 97(11):2791\u20132797","journal-title":"Cancer"},{"issue":"2","key":"2429_CR38","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/cncr.11501","volume":"98","author":"A Ceribelli","year":"2003","unstructured":"Ceribelli A, Gridelli C, De Marinis F et al (2003) Prolonged gemcitabine infusion in advanced non-small cell lung cancer carcinoma: a randomized phase II study of two different schedules in combination with cisplatin. Cancer 98(2):337\u2013343","journal-title":"Cancer"},{"issue":"9","key":"2429_CR39","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1200\/JCO.2008.17.5604","volume":"27","author":"M Perrot de","year":"2009","unstructured":"de Perrot M, Feld R, Cho BC et al (2009) Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 27(9):1413\u20131418. doi: 10.1200\/JCO.2008.17.5604","journal-title":"J Clin Oncol"},{"issue":"3","key":"2429_CR40","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.lungcan.2008.09.008","volume":"64","author":"CW Lee","year":"2009","unstructured":"Lee CW, Murray N, Anderson H et al (2009) Outcomes with first-line platinum-based combination chemotherapy for malignant pleural mesothelioma: a review of practice in British Columbia. Lung Cancer 64(3):308\u2013313. doi: 10.1016\/j.lungcan.2008.09.008","journal-title":"Lung Cancer"},{"issue":"2","key":"2429_CR41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/CAD.0b013e32834d7a1c","volume":"23","author":"V Kovac","year":"2012","unstructured":"Kovac V, Zwitter M, Rajer M et al (2012) A phase II trial of low-dose gemcitabine in a prolonged infusion and cisplatin for malignant pleural mesothelioma. Anticancer Drugs 23(2):230\u2013238. doi: 10.1097\/CAD.0b013e32834d7a1c","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2429_CR42","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.lungcan.2007.02.004","volume":"57","author":"F Rea","year":"2007","unstructured":"Rea F, Marulli G, Bortolotti L et al (2007) Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 57(1):89\u201395","journal-title":"Lung Cancer"},{"issue":"36","key":"2429_CR43","doi-asserted-by":"crossref","first-page":"5770","DOI":"10.1200\/JCO.2007.12.5294","volume":"25","author":"A Bottomley","year":"2007","unstructured":"Bottomley A, Coens C, Efficace F et al (2007) Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma. J Clin Oncol 25(36):5770\u20135776","journal-title":"J Clin Oncol"},{"issue":"3","key":"2429_CR44","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/j.jtcvs.2007.10.054","volume":"135","author":"RM Flores","year":"2008","unstructured":"Flores RM, Pass HI, Seshan VE et al (2008) Extrapleural pneumonectomy versus pleurectomy\/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 135(3):620\u2013626. doi: 10.1016\/j.jtcvs.2007.10.054","journal-title":"J Thorac Cardiovasc Surg"},{"issue":"8","key":"2429_CR45","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S1470-2045(11)70149-8","volume":"12","author":"T Treasure","year":"2011","unstructured":"Treasure T, Lang-Lazdunski L, Waller D et al (2011) Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural\u00a0mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol 12(8):763\u2013772. doi: 10.1016\/S1470-2045(11)70149-8","journal-title":"Lancet Oncol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2429-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2429-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2429-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,25]],"date-time":"2024-05-25T14:14:08Z","timestamp":1716646448000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2429-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4,1]]},"references-count":45,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["2429"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2429-5","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,4,1]]}}}